SteadyMed Ltd. (STDY) Downgraded by ValuEngine to Sell
ValuEngine cut shares of SteadyMed Ltd. (NASDAQ:STDY) from a hold rating to a sell rating in a research report released on Friday morning.
Separately, Zacks Investment Research raised shares of SteadyMed from a sell rating to a hold rating in a research report on Tuesday, July 18th.
Shares of SteadyMed (STDY) traded down 3.85% during midday trading on Friday, hitting $3.75. 71,296 shares of the stock were exchanged. SteadyMed has a 12 month low of $2.25 and a 12 month high of $9.70. The company’s market cap is $99.59 million. The stock has a 50 day moving average price of $6.12 and a 200-day moving average price of $5.88.
SteadyMed (NASDAQ:STDY) last posted its earnings results on Friday, August 11th. The company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.01. The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.26 million. SteadyMed had a negative net margin of 3,179.76% and a negative return on equity of 226.48%. On average, analysts predict that SteadyMed will post ($1.56) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of STDY. Susquehanna International Group LLP bought a new position in SteadyMed during the second quarter worth approximately $1,251,000. Kingdon Capital Management L.L.C. acquired a new position in shares of SteadyMed during the second quarter valued at about $3,170,000. Nexthera Capital LP increased its position in shares of SteadyMed by 6,579.5% in the second quarter. Nexthera Capital LP now owns 360,626 shares of the company’s stock valued at $2,272,000 after buying an additional 355,227 shares during the last quarter. Finally, Federated Investors Inc. PA increased its position in shares of SteadyMed by 37.9% in the second quarter. Federated Investors Inc. PA now owns 4,916,977 shares of the company’s stock valued at $29,296,000 after buying an additional 1,351,766 shares during the last quarter. 57.70% of the stock is currently owned by hedge funds and other institutional investors.
SteadyMed Company Profile
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).
Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.